Navigation Links
New Shire Holding Company Proposal
Date:4/16/2008

further information on Shire, please visit the Company's website: http://www.shire.com.

This announcement does not constitute an offer or invitation to purchase securities.

Morgan Stanley & Co International plc is acting for Shire and Shire Limited and no one else in connection with the Proposals and will not be responsible to anyone other than Shire and Shire Limited for the protections afforded to its clients or for providing advice in relation to the Proposals or the content of this announcement.

This announcement does not constitute an invitation or offer to sell or the solicitation of an invitation or offer to buy any security. None of the securities referred to in this announcement shall be sold, issued, exchanged or transferred in any jurisdiction in contravention of applicable laws.

Notice to United States Residents

This announcement is not an offer of securities in the United States.

The Shire Limited ordinary shares to be issued in connection with the Proposals will not be, and are not required to be, registered with the US Securities and Exchange Commission under the US Securities Act of 1933, as amended, in reliance on the exemption from registration provided by Section 3(a)(10) thereof.

The "Safe Harbor" Statement Under the Private Securities Litigation Reform Act of 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research; product development including, but not limited to, the successful development of JUVISTA(R) (Human TGF(BETA)3) and velaglucerase alfa (GA-GCB); manu
'/>"/>

SOURCE Shire PLC
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Shire to Introduce a New UK Listed Holding Company
2. Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis
3. Shire plc: Long Term Incentive Plan
4. Shire plc: IFRS Results for the Year Ending December 31, 2007
5. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
6. Shire plc: Correction Re Website
7. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
8. Shire Engages Palio
9. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
10. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
11. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/16/2010)... Stock Exchange Symbol: MS , ... , , ... ... EDMONTON , March 16 ... ...
(Date:3/16/2010)... PharmAthene, Inc. (Amex: PIP ) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that its financial results ... ... , ... ... ...
(Date:3/16/2010)... March 16 The Gynecologic Cancer Foundation (GCF) and the Claudia ... as the first recipient of the $50,000 GCF/Claudia Cohen Prize for Outstanding ... (SGO) 41st Annual Meeting on Women,s Cancer, meeting in San Francisco ... ... ...
(Date:3/16/2010)... (LSE: SHP,NASDAQ; SHPGY), announces that it has received a Paragraph IV Notice ... New Drug Application ("ANDA") for a generic version of Shire,s 1,mg, 2mg, ... ... ... , ...
Breaking Biology Technology:BioMS Medical Announces 2009 Year End Results 2BioMS Medical Announces 2009 Year End Results 3BioMS Medical Announces 2009 Year End Results 4BioMS Medical Announces 2009 Year End Results 5BioMS Medical Announces 2009 Year End Results 6BioMS Medical Announces 2009 Year End Results 7BioMS Medical Announces 2009 Year End Results 8BioMS Medical Announces 2009 Year End Results 9BioMS Medical Announces 2009 Year End Results 10PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010 2PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010 3Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher 2Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher 3Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher 4Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher 5Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 2Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 3Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 4
... , , ... This Application Report is part of a series documenting,culture growth ... bacteria, as well as mammalian,plant cells and insect cells., ... , Pichia ...
... , ... , , ... HPLC by utilizing the Prominence,hardware series. In this respect, we are ... while providing high,reliability and expandability not available with other fast,LC systems., ...
... and Roy Eksteen, Tosoh Bioscience LLC, Montgomeryville, Pennsylvania and,Scott Lauder, Lexigen Pharmaceuticals, Lexington, ... Introduction: , ... robustness. Factors such as elution profile, peak shape, ... be consistent by GMP/GLP protocols. During a recent method , ...
Other Biology Technology:P. pastoris Fermentation using a BioFlo 110 Benchtop Fermentor 2P. pastoris Fermentation using a BioFlo 110 Benchtop Fermentor 3P. pastoris Fermentation using a BioFlo 110 Benchtop Fermentor 4P. pastoris Fermentation using a BioFlo 110 Benchtop Fermentor 5P. pastoris Fermentation using a BioFlo 110 Benchtop Fermentor 6P. pastoris Fermentation using a BioFlo 110 Benchtop Fermentor 7P. pastoris Fermentation using a BioFlo 110 Benchtop Fermentor 8Prominence UFLC 2Prominence UFLC 3Prominence UFLC 4Prominence UFLC 5Prominence UFLC 6Prominence UFLC 7Prominence UFLC 8Mobile Phase Optimization for the Analysis of an Antibody-Based Fusion Protein and Aggregates using a TSKgel Super SW3000 Size-Exclusion Column 2Mobile Phase Optimization for the Analysis of an Antibody-Based Fusion Protein and Aggregates using a TSKgel Super SW3000 Size-Exclusion Column 3
(Date:3/18/2010)... can live for twenty years, fertilizing millions of eggs ... activity. , Danish researchers who have studied ants ... 1992 discovered that in both ant and bee species ... fluid favors the survival of its own sperm over ... stored, leafcutter ant queens neutralize male-male sperm competition with ...
(Date:3/18/2010)... available in Spanish . , Feeding ... as part of their regular diet makes them ... a study by Agricultural Research Service (ARS) scientists ... and overall behavioral activity among young female pigs ... acquired through diet, is the precursor for the ...
(Date:3/18/2010)... Biotech, Inc., ( www.genwaybio.com ) the US-based diagnostic company ... is expanding this cancer testing program internationally. An ... YouTM Cancer Assessment in Greece starting in April. ... as well. GenWay currently offers this test in ... Sergey Sikora, Vice President of Business Development, said, "The ...
Breaking Biology News(10 mins):Females shut down male-male sperm competition in leafcutter ants 2Tryptophan-enriched diet reduces pig aggression 2Moravia Worldwide Names George Krawczyk as Sales Director for Ireland and UK 61905 1Moravia Worldwide Names George Krawczyk as Sales Director for Ireland and UK 61905 2Barbara Fentress Designer of the Denver International Airport and Convention Center Offers Her Private Mansion at Absolute Auction 61902 1Barbara Fentress Designer of the Denver International Airport and Convention Center Offers Her Private Mansion at Absolute Auction 61902 2Ophthalmic Equipment Distributor Latham 26amp 3B Phillips SE Division Unveils Website 61899 1Ophthalmic Equipment Distributor Latham 26amp 3B Phillips SE Division Unveils Website 61899 2Ophthalmic Equipment Distributor Latham 26amp 3B Phillips SE Division Unveils Website 61899 3
... When Yadong Wang, a chemist by training, first ventured ... that his peers would have considered him crazy. , ... signals often conducted by neurotransmitters (chemical messengers) to communicate ... he could build neurotransmitters into the material used to ...
... Manchester researchers are recruiting people with backache caused by ... first ever study to discover if therapeutic ultrasound can ... team at the University's Centre for Rehabilitation Science need ... less than 12 weeks, are not pregnant and have ...
... high tech tools, researchers have identified three proteins that ... 20 months before the rejection occurred. , Lung transplant ... about 45% over five years, said lead investigator and ... to predict which transplants will fail, and when signs ...
Other Biology News:Dopamine used to prompt nerve tissue to regrow 2Proteins may predict lung transplant rejection 2Proteins may predict lung transplant rejection 3
... Oligo Spots and complementary RNA Spikes for ... Use for glass array printing and for ... transcription, cDNA labeling, hybridization stringency and background. ... PCR Spots and Oligo Spots, and complementary ...
MOUSE ANTI DUCK IgY LIGHT CHAIN...
MOUSE ANTI S. MUTANS PEPTIDOGLYCAN...
ANTI END CEL LUNG AG...
Biology Products: